Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent SRS and CDK4/6 Inhibitors in Breast Cancer Brain Metastases
NCT04585724Phase 1Withdrawn
- Sponsor
- Emory University
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of abemaciclib, ribociclib and palbociclib in breast cancer (3 arms), sponsored by Emory University. Primary endpoint: Incidence of grade 3+ radiation therapy oncology central nervous system toxicity at 3 months. Planned start Jun 2020; status: withdrawn.
02
Drugs
abemaciclibribociclibpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04585724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585724.